Latest News

Ceapro Inc. Presents its PGX Technology at the 15th European Meeting on Supercritical Fluids

EDMONTON, ALBERTA – May 9, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that it presented this morning its PGX Technology at the 15th European

Read more

Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook – Ceapro expects to commence clinical program with avenanthramides as anti-inflammatory compound before year end – Pilot clinical study to develop beta glucan as a cholesterol reducer expected to initiate in the third quarter of 2016

EDMONTON, ALBERTA – April 18, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a business update for the year ended December 31, 2015 and a

Read more

Ceapro Inc. Reports 2015 Financial Results, Best Financial Year in Company’s History – Ceapro posts highest revenues, profits and cash flows reported in Company’s history for both Q4 2015 and FY 2015

EDMONTON, ALBERTA – April 14, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced its financial results for the twelve-months ended December 31, 2015. The Company’s

Read more

Ceapro Announces Renewal of a Long Term License and Distribution Agreement with Symrise – Symrise is leading global provider of active ingredients for the distribution and commercialization of Ceapro’s high value active ingredients in the cosmetic market.

EDMONTON, ALBERTA, April 6, 2016 – Ceapro Inc. (CZO –V) (“Ceapro” or “the Company”) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a new long term agreement with German-based multinational, Symrise AG,

Read more

Ceapro Inc. Announces Research Partnership with McMaster University for Its Pressurized Gas Expanded (PGX) Technology – McMaster University researchers awarded grant from Natural Sciences and Engineering Research Council of Canada to advance Ceapro’s application of its PGX Technology – Ceapro to host and train graduate students and process material with PGX in its Edmonton-based laboratories for the next three years

EDMONTON, ALBERTA – March 1, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company will initiate an extensive research program in collaboration with

Read more

Ceapro Inc. Issued U.S. Patent for Enabling Pressurized Gas Expanded (PGX) Technology

EDMONTON, ALBERTA – February 3, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that the Company has received issuance from the U.S. Patent and Trademark

Read more

Ceapro to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference – Presentation with live webcast on Tuesday, January 19th at 2:30 p.m. ET

EDMONTON, ALBERTA – January 13, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at NobleCon12, the Noble Financial Capital Markets’ 12th

Read more

Ceapro to Present at Biotech Showcase™ 2016 on January 12, 2016 – Presentation with live webcast on Tuesday, January 12th at 3:30 p.m. PT

EDMONTON, ALBERTA – January 5, 2016 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 8th Annual Biotech Showcase™ conference on

Read more

Ceapro Announces Issuance of Shares for Debt Reduction Initiative

EDMONTON, ALBERTA – December 24, 2015 – Ceapro Inc.  (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that pursuant to debt settlement agreements with each of its Directors, previously

Read more

Ceapro Strengthens Balance Sheet with Shares for Debt Reduction Initiative

EDMONTON, ALBERTA – December 3, 2015 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that pursuant to debt settlement agreements with each of its Directors, it

Read more
Page 3 of 1012345...10...Last »